Who owns ALNYLAM PHARMACEUTICALS INC NOTE 1.000 9/1?
- CUSIP Number: 02043qab3
Tip: Access positions for across all investors
Analyze quarterly positions in Alnylam Pharmaceuticals Inc Note 1.000 9/1 with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Alnylam Pharmaceuticals Inc Note 1.000 9/1 stock
Who bought or sold ALNYLAM PHARMACEUTICALS INC NOTE 1.000 9/1 this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Steelhead Partners | 60M | $77B | 100% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 32M | $41M | 87% | Mar 2026 |
|
| Alberta Investment Management Corporation | 25M | $32M | 0% | Mar 2026 |
|
| DeepCurrents Investment Group | 24M | $31M | 100% | Mar 2026 |
|
| State Street Corporation | 22M | $32M | 4% | Dec 2025 |
|
| FMR | 20M | $29M | 17% | Dec 2025 |
|
| CSS | 19M | $24M | 100% | Mar 2026 |
|
| BlackRock | 17M | $21M | 27% | Mar 2026 |
|
| MacKay Shields | 15M | $19M | 0% | Mar 2026 |
|
| Manufacturers Life Insurance Company | 14M | $18M | -27% | Mar 2026 |
|
| Bank of America Corporation | 11M | $14M | 100% | Mar 2026 |
|
| Universal- Beteiligungs- und Servicegesellschaft mbH | 8.2M | $11M | 81% | Mar 2026 |
|
| Two Sigma Investments | 6.0M | $7.7M | 100% | Mar 2026 |
|
| Citigroup | 5.7M | $7.2M | 100% | Mar 2026 |
|
| Warberg Asset Management | 5.0M | $6.4M | 0% | Mar 2026 |
|
| Amundi | 5.0M | $6.5k | 0% | Mar 2026 |
|
| Bnp Paribas Investment Partners | 4.8M | $7.0M | 100% | Dec 2025 |
|
| SSI Investment Management | 4.1M | $5.3M | 0% | Mar 2026 |
|
| Nicholas Investments Partners | 3.2M | $4.7M | 0% | Dec 2025 |
|
| Morgan Stanley | 3.1M | $4.0M | 100% | Mar 2026 |
|
| State of Wisconsin Investment Board | 3.0M | $4.4M | 0% | Dec 2025 |
|
| Invesco | 2.5M | $3.2M | 0% | Mar 2026 |
|
| Franklin Resources | 2.2M | $2.9M | 0% | Mar 2026 |
|
| Nomura Asset Management International | 2.1M | $2.7M | 100% | Mar 2026 |
|
| Union Bancaire Privee, UBP SA | 2.0M | $2.2M | 0% | Mar 2026 |
|
| Lord, Abbett & Co | 1.2M | $1.5M | -84% | Mar 2026 |
|
| Kim | 1.0M | $1.3M | 100% | Mar 2026 |
|
| Agf Management | 950k | $1.2M | 0% | Mar 2026 |
|
| Wells Fargo & Company | 910k | $1.2M | -36% | Mar 2026 |
|
| Leucadia National Corporation | 681k | $874k | 10% | Mar 2026 |
|
| Goldman Sachs Group | 374k | $479k | -74% | Mar 2026 |
|
| Sei Investments | 251k | $322k | 0% | Mar 2026 |
|
| Central Pacific Bank - Trust Division | 224k | $287k | 0% | Mar 2026 |
|
| Bank of New York Mellon | 215k | $277k | 100% | Mar 2026 |
|
| Oppenheimer Asset Management | 81k | $104k | -1% | Mar 2026 |
|
| Virtus ETF Advisers | 36k | $46k | 0% | Mar 2026 |
|
| Barclays | 27k | $40k | 100% | Dec 2025 |
|
| Stephens | 24k | $31k | 0% | Mar 2026 |
|
| UBS Group | 23k | $29k | 3284% | Mar 2026 |
|
| Boussard & Gavaudan Investment Management | 21k | $31M | 60% | Dec 2025 |
|
| Balboa Wealth Partners | 14k | $18k | -7% | Mar 2026 |
|
| Mml Investors Services | 10k | $13k | 0% | Mar 2026 |
|
| Loomis, Sayles and | 9.0k | $3.6M | 100% | Dec 2025 |
|
| Royal Bank of Canada | 2.0k | $3.0k | 100% | Mar 2026 |
|
| Us Bancorp | 2.0k | $2.9k | 0% | Dec 2025 |
|
| Alken Asset Management | 1.0k | $1.3M | 0% | Mar 2026 |
|
| Steward Partners Investment Advisory | 1.0k | $1.3k | -50% | Mar 2026 |
|
Who sold out of Alnylam Pharmaceuticals Inc Note 1.000 9/1?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Ing Investment Management | Dec 2025 | 140M | $206M |
| Jpmorgan Chase & Co | Sep 2025 | 3.3M | $5.4M |
| Wellington Management Company | Sep 2025 | 2.5M | $4.1M |
| Westwood Holdings | Dec 2025 | 2.1M | $2.1M |
| Macquarie Group | Sep 2025 | 2.1M | $3.4M |
| Gabelli Funds | Sep 2025 | 2.0M | $3.3M |
| Calamos Advisors | Dec 2025 | 372k | $549k |
| Calamos Wealth Management | Dec 2025 | 66k | $97k |
| Goss Wealth Management | Dec 2025 | 10k | $15k |
| CoreCap Advisors | Dec 2025 | 2.0k | $2.9k |